Key facts
- This page summarizes Katharyn Field's Form 4 filing for Virpax Pharmaceuticals, Inc. (VRPX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jul 2024, 16:10.
Katharyn Field - 05 Jul 2024 Form 4 Insider Report for Virpax Pharmaceuticals, Inc. (VRPX)
- Reporting relationship
- Director
- Issuer ticker
- VRPX
- Reported as of
- 05 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jul 2024, 16:10:52 UTC
- Next SEC filing
- 27 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vinay Shah, Attorney-in-fact for Katharyn Field
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Katharyn Field filed Form 4 for Virpax Pharmaceuticals, Inc. (VRPX) on 10 Jul 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRPX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +2,500
- Change %
- Price
- $0.000000
- Shares after
- 2,500
- Date
- 05 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,500
- Exercise price
- $0.5780
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in full on the twelve-month anniversary of the grant date.